Trinity Biotech plc – NASDAQ:TRIB
Trinity Biotech stock price today
$1.5
+0.69
+87.06%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 4 hours
Trinity Biotech stock price monthly change
-75.62%
month
Trinity Biotech stock price quarterly change
-75.62%
quarter
Trinity Biotech stock price yearly change
+105.64%
year
Trinity Biotech key metrics
Market Cap | 9.09M |
Enterprise value | N/A |
P/E | -0.72 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 0.42 |
Price/Book | 4.94 |
PEG ratio | N/A |
EPS | -2.75 |
Revenue | 56.70M |
EBITDA | -12.77M |
Income | -21.52M |
Revenue Q/Q | -0.84% |
Revenue Y/Y | -19.94% |
Profit margin | -42.21% |
Oper. margin | -18.92% |
Gross margin | 30.22% |
EBIT margin | -18.92% |
EBITDA margin | -22.54% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTrinity Biotech stock price history
Trinity Biotech stock forecast
Trinity Biotech financial statements
| Jun 2023 | 13.89M | -5.98M | -43.09% |
|---|---|---|---|
| Sep 2023 | 14.67M | -6.72M | -45.79% |
| Dec 2023 | 13.42M | -5.50M | -40.97% |
| Mar 2024 | 14.70M | -3.31M | -22.56% |
| Dec 2023 | 13.42M | -5.50M | -40.97% |
|---|---|---|---|
| Mar 2024 | 14.70M | -3.31M | -22.56% |
| Sep 2025 | 18.5M | -1.86M | -10.07% |
| Dec 2025 | 19M | -1.50M | -7.94% |
Analysts Price target
Financials & Ratios estimates
| 2024-05-23 | -0.54 | -0.37 |
|---|---|---|
| 2024-11-15 | -0.54 | -0.43 |
| Jun 2023 | 71990000 | 83.37M | 115.81% |
|---|---|---|---|
| Sep 2023 | 63597000 | 81.08M | 127.5% |
| Dec 2023 | 59435000 | 83.38M | 140.29% |
| Mar 2024 | 90305000 | 113.16M | 125.31% |
| Jun 2023 | -4.41M | 27.86M | -13.45M |
|---|---|---|---|
| Sep 2023 | -4.66M | -886K | -2.43M |
| Dec 2023 | -966K | -890.99K | -555K |
| Mar 2024 | -4.82M | -13.96M | 20.85M |
Trinity Biotech alternative data
| Aug 2023 | 398 |
|---|---|
| Sep 2023 | 398 |
| Oct 2023 | 398 |
| Nov 2023 | 398 |
| Dec 2023 | 398 |
| Jan 2024 | 398 |
| Feb 2024 | 398 |
| Mar 2024 | 398 |
| Apr 2024 | 398 |
| May 2024 | 398 |
| Jun 2024 | 380 |
| Jul 2024 | 380 |
Trinity Biotech other data
3.36%
-1.41%
of TRIB is owned by hedge funds
4.62M
-1.94M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 23 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 4 Apr 2024 | Q4 2023 Earnings Call Transcript |
| Q2 2023 3 Oct 2023 | Q2 2023 Earnings Call Transcript |
| Q4 2022 23 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Ronan O'Caoimh (1956) Chairman & Chief Executive Officer | $1,050,000 |
Mr. Kevin Tansley (1971) Executive Director | $757,000 |
Mr. John Gillard (1981) Chief Financial Officer, Company Sec. & Executive Director | $312,000 |
Dr. James Walsh Ph.D. (1958) Executive Director | $38,000 |
-
What's the price of Trinity Biotech stock today?
One share of Trinity Biotech stock can currently be purchased for approximately $1.5.
-
When is Trinity Biotech's next earnings date?
Unfortunately, Trinity Biotech's (TRIB) next earnings date is currently unknown.
-
Does Trinity Biotech pay dividends?
No, Trinity Biotech does not pay dividends.
-
How much money does Trinity Biotech make?
Trinity Biotech has a market capitalization of 9.09M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 24% to 56.83M US dollars. Trinity Biotech made a loss 24.02M US dollars in net income (profit) last year or -$0.43 on an earnings per share basis.
-
What is Trinity Biotech's stock symbol?
Trinity Biotech plc is traded on the NASDAQ under the ticker symbol "TRIB".
-
What is Trinity Biotech's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Trinity Biotech?
Shares of Trinity Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Trinity Biotech's key executives?
Trinity Biotech's management team includes the following people:
- Mr. Ronan O'Caoimh Chairman & Chief Executive Officer(age: 69, pay: $1,050,000)
- Mr. Kevin Tansley Executive Director(age: 54, pay: $757,000)
- Mr. John Gillard Chief Financial Officer, Company Sec. & Executive Director(age: 44, pay: $312,000)
- Dr. James Walsh Ph.D. Executive Director(age: 67, pay: $38,000)
-
How many employees does Trinity Biotech have?
As Jul 2024, Trinity Biotech employs 380 workers, which is 5% less then previous quarter.
-
When Trinity Biotech went public?
Trinity Biotech plc is publicly traded company for more then 32 years since IPO on 21 Oct 1992.
-
What is Trinity Biotech's official website?
The official website for Trinity Biotech is trinitybiotech.com.
-
How can i contact Trinity Biotech?
Trinity Biotech can be reached via phone at +353 1 276 9800.
Trinity Biotech company profile:
Trinity Biotech plc
trinitybiotech.comExchange:
NASDAQ
Full time employees:
380
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
IDA Business Park
Bray, A98 H5C8
Bray, A98 H5C8
CIK: 0000888721
ISIN: US8964385046
CUSIP: 896438306
